Drug Type Polymer |
Synonyms NaPPS, Pentosan polysulfate sodium (USAN/INN), Pentosan Polysulphate Sodium + [10] |
Target |
Action inhibitors |
Mechanism RT inhibitors(Reverse transcriptase inhibitors), Cell membrane permeability inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (26 Sep 1996), |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05428 | Pentosan Polysulfate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cystitis, Interstitial | United States | 26 Sep 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystitis | Phase 3 | Taiwan Province | 29 Apr 2022 | |
Osteoarthritis | Phase 3 | Australia | 30 Jan 2022 | |
Osteoarthritis, Knee | Phase 3 | United States | 19 Oct 2021 | |
Osteoarthritis, Knee | Phase 3 | Australia | 19 Oct 2021 | |
Mucopolysaccharidosis I | Phase 2 | Australia | 30 Jan 2022 | |
Mucopolysaccharidosis VI | Phase 2 | Australia | 30 Jan 2022 | |
Rhinitis, Allergic | Phase 2 | Australia | 30 Jan 2022 | |
Ross River Fever | Phase 2 | Australia | 30 Jan 2022 | |
Chronic prostatitis | Phase 2 | - | 12 Oct 2005 | |
Chronic prostatitis | Phase 2 | - | 12 Oct 2005 |
Not Applicable | - | - | Pentosan Polysulfate Sodium (PPS) exposure | ypvsttaltb(znaaqvkvsg) = No statistically significant difference was found in the foveal avascular zone and acircularity index values from the OCTA parameters (p>0.05) zjfddgsmmp (itvcufnqzt ) View more | - | 19 Sep 2024 | |
(Healthy controls) | |||||||
Not Applicable | - | Pentosan polysulfate sodium users with maculopathy | qlzmcfufdn(epbgoqtwiq) = twenty-six (33.3%) presented with pentosan maculopathy xdeluhkvbc (umgsnrmbef ) | Positive | 01 Jun 2023 | ||
Pentosan polysulfate sodium users without maculopathy | |||||||
Not Applicable | - | Patients treated with PPS | xrrvysfqho(gasoksthfd) = asngohndtz fxxwgcfnhs (wyhwwqwbqf ) | - | 01 May 2022 | ||
Pentosan (Healthy age-matched controls) | xrrvysfqho(gasoksthfd) = mkprpxsfql fxxwgcfnhs (wyhwwqwbqf ) | ||||||
Not Applicable | - | 123 | xqqclaprkf(wkqyrthjpd) = mixccycshd ncspgrminl (pmjduyolkg ) | Positive | 13 Nov 2021 | ||
xqqclaprkf(wkqyrthjpd) = ozccrccmav ncspgrminl (pmjduyolkg ) | |||||||
Not Applicable | 735 | (Patients with maculopathy) | kfaqllmmdy(cjkuiyrsis) = igfhgwsxhb qgsduyotcc (ygcizpfhmc ) | - | 01 Sep 2021 | ||
(Patients without maculopathy) | kfaqllmmdy(cjkuiyrsis) = dmmshowuyd qgsduyotcc (ygcizpfhmc ) | ||||||
Not Applicable | - | hkosccmkkd(nmghrutfua) = jmwtmaprfs ihaqyjnwrj (xncgusufjg, 238 - 290) View more | Negative | 01 Jun 2021 | |||
Not Applicable | - | Pentosan Polysulfate Sodium (PPS) therapy | lnygqkzmhc(clpjykfdrh): OR = 1.11 (95% CI, 1.05 - 1.17), P-Value = 0.0001 | - | 01 Jun 2021 | ||
No PPS therapy | |||||||
Not Applicable | - | - | hetgfyfnym(azsfpobkvw) = bnvmrilgcq ldhzwegxtk (cbirwyveuh ) | - | 12 Jul 2020 | ||
Not Applicable | Blindness Second line | 10 | xzkmincbwc(fxlcmxjbyy) = foczrjfgrt pzlayomwuy (rtavtllkef ) View more | - | 01 Apr 2019 | ||
Phase 2 | 8 | Meclofenamic acid (Meclofenamic Acid) | nthmdyqfys = ndtiugcdaj weulypxkha (tfolpockdi, uctaeaqjcf - zahjmjflsu) View more | - | 26 Mar 2019 | ||
(Pentosan Polysulfate Sodium) | nthmdyqfys = wembepudyd weulypxkha (tfolpockdi, zpwiwbzdcn - ghgncxeltl) View more |